New drug duo takes aim at Tough-to-Treat colon cancer
NCT ID NCT06008119
Summary
This study is for people with advanced colorectal cancer that has spread and has a specific genetic change called BRAF V600E, and whose cancer has worsened after at least one prior treatment. It aims to see if a new combination of two targeted drugs (tunlametinib and vemurafenib) works better and is safer than standard chemotherapy chosen by the doctor. The main goal is to see if the drug combo can keep the cancer from growing for a longer time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Oncology Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.